Tersera Theraps Llc   Report issue

Contributed to NME For profit Phase 2
Founded: Lake Forest IL United States (2016)
Status: No NME R&D (2016)

Organization Overview

First Clinical Trial
2019
NCT03942653
First Marketed Drug
2016
ergotamine
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Chandrikha Chandrasekhara | TERSERA | TerSera Therapeutics | TerSera Therapeutics LLC | TERSERA THERAPS LLC

Indications

Approved Indications


 

Prostatic Neoplasms

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Neoplasms (Phase 2)

Salivary Gland Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 6